Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 16/20 | 0.63 |
| ▸ | EED | O75530 | 10/20 | 0.59 |
| ▸ | RBBP4 | Q09028 | 10/20 | 0.59 |
| ▸ | SUZ12 | Q15022 | 10/20 | 0.59 |
| ▸ | AEBP2 | Q6ZN18 | 10/20 | 0.59 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20549596 | 1.00 | EZH2 (0.63) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15709904 | 0.93 | EZH2 (0.68) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15710350 | 0.91 | EZH2 (0.61) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15710954 | 0.90 | EED (0.70) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13467954 | 0.85 | EZH2 (0.81) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15390840 | 0.85 | EED (0.77) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL18222679 | 0.84 | EZH2 (0.65) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL18222684 | 0.84 | EZH2 (0.65) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20549597 | 0.82 | EZH2 (0.63) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15710274 | 0.82 | EZH2 (0.68) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10420775-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180318309-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10420775-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-20180318309-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.